Gabapentin vs Amitriptyline

Both gabapentin and amitriptyline are effective for neuropathic pain, with numbers needed to treat (NNT) of approximately 6–8 for gabapentin and 3–4 for amitriptyline for 50% pain reduction ^[3]. A 2019 Cochrane review found amitriptyline to have moderate-quality evidence for efficacy in neuropathic pain, though the effect size may be overestimated due to small trial sizes ^[2]. Gabapentin has more robust trial data, particularly for diabetic peripheral neuropathy and postherpetic neuralgia, which are its FDA-approved indications beyond epilepsy ^[1]. For fibromyalgia, gabapentin has shown benefit in trials, though pregabalin (a related drug) has the FDA indication ^[3]. Amitriptyline at low doses (10–50 mg) is widely used off-label for fibromyalgia and has positive trial data. For migraine prophylaxis, amitriptyline has Level A evidence and an established role, while gabapentin has weaker evidence for this use ^[4]. In the OPTION-DM trial comparing treatments for painful diabetic neuropathy, amitriptyline and pregabalin/gabapentin-class drugs showed similar efficacy, with combination therapy outperforming monotherapy ^[3].

Side-effect profiles differ substantially. Gabapentin commonly causes dizziness (17–28%), somnolence (16–21%), peripheral edema (2–8%), and weight gain ^[1]. Cognitive effects (difficulty concentrating, confusion) occur particularly in elderly patients. Gabapentin has recently been recognized as having abuse potential, especially in patients with opioid use disorders, and some states have classified it as a controlled substance ^[3]. Amitriptyline's anticholinergic effects are its primary liability: dry mouth (40–60%), constipation (15–25%), urinary retention, blurred vision, and tachycardia ^[2]. Sedation is pronounced and dose-dependent. Amitriptyline carries cardiac risks including QTc prolongation and arrhythmia, making an ECG advisable before initiating treatment in older adults or those with cardiac disease ^[4]. Weight gain occurs with both drugs but is generally more significant with amitriptyline (2–5 kg). Amitriptyline is dangerous in overdose (potentially fatal cardiac toxicity), while gabapentin overdose is rarely fatal ^[2]. Neither drug should be abruptly discontinued.

Both medications are available as inexpensive generics. Generic gabapentin 300 mg (90 capsules for three-times-daily dosing) costs $4–15 ^[1]. Generic amitriptyline 25 mg (30 tablets) costs $4–10 ^[2]. Both are among the cheapest prescription medications available and are covered by all insurance formularies at the lowest copay tier. Extended-release gabapentin formulations (Gralise, Horizant) are significantly more expensive ($200–400/month).

Dosing schedules differ meaningfully. Gabapentin is typically taken three times daily due to its short half-life (5–7 hours), starting at 100–300 mg at bedtime and titrating to 300–600 mg three times daily (maximum 3,600 mg/day) ^[1]. This three-times-daily dosing is less convenient but allows flexible titration. Amitriptyline is taken once daily at bedtime (leveraging its sedative effect for sleep benefit), starting at 10–25 mg and titrating to 25–75 mg for pain (maximum 150 mg/day for depression) ^[2]. Amitriptyline's once-nightly dosing is simpler and can improve sleep quality as a secondary benefit. Gabapentin absorption is saturable and non-linear — bioavailability decreases at higher doses, which complicates dose optimization ^[3]. Neither drug requires routine blood level monitoring for pain indications, though amitriptyline levels can be checked if toxicity or non-adherence is suspected.

Gabapentin may be preferred for patients with diabetic neuropathy or postherpetic neuralgia (strongest evidence base), patients at risk for cardiac arrhythmia (no QTc prolongation), patients who cannot tolerate anticholinergic effects, or elderly patients where TCA risks are heightened ^[1][3]. Amitriptyline may be preferred for patients with comorbid insomnia (sedative effect is beneficial), migraine prophylaxis (Level A evidence), patients with comorbid depression (treats both conditions), or patients who prefer once-daily dosing ^[2][4]. For patients who fail monotherapy with either drug, combination gabapentin plus amitriptyline may offer superior pain relief based on the OPTION-DM trial results ^[3]. Both drugs should be started at low doses and titrated gradually. Consult your healthcare provider to choose the best option for your type of neuropathic pain and comorbidities.